Childhood tuberculosis: A concern of the modern world

European Respiratory Review

Volumn 23, Issue 133, 2014, Pages 278-291

  Hamzaoui, Agnes ^a   Yaalaoui, Sadok ^a   Cherif, Fatma Tritar ^a   Saidi, Leila Slim ^a   Berraies, Anissa ^a  

^a ABDERRAHMAN MAMI HOSPITAL   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; CHILD; COMPLICATION; GENETICS; HUMAN; IMMUNOLOGY; MULTIDRUG RESISTANT TUBERCULOSIS; TUBERCULOSIS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; CHILD; HUMANS; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84906859761     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00005314     Document Type: Article

References (135)

1. Sandgren A, Cuevas LE, Dara M, et al. Childhood tuberculosis: progress requires an advocacy strategy now. Eur Respir J 2012; 40: 294-297.
2. Perez-Velez CM, Marais BJ. Tuberculosis in children. N Engl J Med 2012; 367: 348-361.
3. World Health Organization. Roadmap for Childhood Tuberculosis: Towards Zero Deaths. Geneva, WHO, 2013
4. Gomes VF, Andersen A, Wejse C, et al. Impact of tuberculosis exposure at home on mortality in children under 5 years of age in Guinea-Bissau. Thorax 2011; 66: 163-167.
5. Wu XR, Yin QQ, Jiao AX, et al. Pediatric tuberculosis at Beijing Children's Hospital: 2002-2010. Pediatrics 2012; 130: e1433-e1440.
6. Zar HJ, Udwadia ZF. Advances in tuberculosis 2011-2012. Thorax 2013; 68: 283-287.
7. Teo SS, Alfaham M, Evans MR, et al. An evaluation of the completeness of reporting of childhood tuberculosis. Eur Respir J 2009; 34: 176-179.
8. Soborg B, Koch A, Thomsen VØ, et al. Ongoing tuberculosis transmission to children in Greenland. Eur Respir J 2010; 36: 878-884.
9. Garrido JB, Alías Hernández I, Bonillo Perales A, et al. Usefulness of thoracic CT to diagnose tuberculosis disease in patients younger than 4 years of age. Pediatr Pulmonol 2012; 47: 895-902.
10. Pang J, Teeter LD, Katz DJ, et al. Epidemiology of tuberculosis in young children in the United States. Pediatrics 2014; 133: e494-e504.
11. Baghaie N, Khalilzadeh S, Bolursaz MR, et al. Contact tracing of a 15-year-old girl with smear-negative pulmonary tuberculosis in Tehran. East Mediterr Health J 2012; 18: 399-401.
12. Verver S, van Loenhout-Rooyackers JH, Bwire R, et al. Tuberculosis infection in children who are contacts of immigrant tuberculosis patients. Eur Respir J 2005; 26: 126-132.
13. World Health Organization. Recommendations for Investigating Contacts of Persons with Infectious Tuberculosis in Low- and Middle-Income Countries. Geneva, WHO, 2012.
14. Tagarro A, Jiménez S, Sánchez A, et al. Brote de tuberculosis en un colegio de primaria: descripcion y consideraciones sobre el valor del jugo gastrico en el manejo de microepidemias [Tuberculosis outbreak in a primary school: description and reflections on the value of gastric juice in the management of micro-epidemics]. Enferm Infecc Microbiol Clin 2011; 29: 90-95.
15. Døllner H, Ramm CT, Harstad I, et al. Risk of developing tuberculosis after brief exposure in Norwegian children: results of a contact investigation. BMJ Open 2012; 2: e001816.
16. Mandalakas AM, Kirchner HL, Lombard C, et al. Well-quantified tuberculosis exposure is a reliable surrogate measure of tuberculosis infection. Int J Tuberc Lung Dis 2012; 16: 1033-1039.
17. Middelkoop K, Bekker LG, Morrow C, et al. Childhood infection and disease: a spatial and temporal transmission analysis in a South African township. S Afr Med J 2009; 99: 738-743.
18. Jain SK, Ordonez A, Kinikar A, et al. Pediatric tuberculosis in young children in India: a prospective study. Biomed Res Int 2013; 2013: 783698.
19. Marais BJ, Parker SK, Verver S, et al. Primary and postprimary or reactivation tuberculosis: time to revise confusing terminology? AJR Am J Roentgenol 2009; 192: W198.
20. Zignol M, Sismanidis C, Falzon D, et al. Multidrug-resistant tuberculosis in children: evidence from global surveillance. Eur Respir J 2013; 42: 701-707.
21. Donald PR, Marais BJ, Barry CE 3rd. Age and the epidemiology and pathogenesis of tuberculosis. Lancet 2010; 375: 1852-1854.
22. Leung CC, Yew WW, Au KF, et al. A strong tuberculin reaction in primary school children predicts tuberculosis in adolescence. Pediatr Infect Dis J 2012; 31: 150-153.
23. Dangor Z, Izu A, Moore DP, et al. Temporal association in hospitalizations for tuberculosis, invasive pneumococcal disease and influenza virus illness in South African children. PLoS One 2014; 9: e91464.
24. Marais BJ, Graham SM, Cotton MF, et al. Diagnostic and management challenges for childhood tuberculosis in the era of HIV. J Infect Dis 2007; 196: Suppl. 1, S76-S85.
25. Auld AF, Tuho MZ, Ekra KA, et al. Tuberculosis in human immunodeficiency virus-infected children starting antiretroviral therapy in Côte d'Ivoire. Int J Tuberc Lung Dis 2014; 18: 381-387.
26. Oesch Nemeth G, Nemeth J, Altpeter E, et al. Epidemiology of childhood tuberculosis in Switzerland between 1996 and 2011. Eur J Pediatr 2014; 173: 457-462.
27. Hatleberg CI, Prahl JB, Rasmussen JN, et al. A review of paediatric tuberculosis in Denmark: 10-year trend, 2000-2009. Eur Respir J 2014; 43: 863-871.
28. Rodríguez Valín E, Garrido Estepa M, Villarrubia Enseñat S, et al. Epidemiologia de la tuberculosis pediatrica en Espana, 2005-2009 [Epidemiology of childhood tuberculosis in Spain: 2005-2009]. Rev Esp Salud Publica 2012; 86: 49-59.
29. Abubakar I, Laundy MT, French CE, et al. Epidemiology and treatment outcome of childhood tuberculosis in England and Wales: 1999-2006. Arch Dis Child 2008; 93: 1017-1021.
30. Ruwende JE, Sanchez-Padilla E, Maguire H, et al. Recent trends in tuberculosis in children in London. J Public Health (Oxf) 2011; 33: 175-181.
31. Siegel D, Song X, Klontz K, et al. Epidemiology of childhood tuberculosis: use and evaluation of the pediatric health information system to assess local and national incidence. Pediatr Infect Dis J 2011; 30: 428-430.
32. Tuberculosis Surveillance Center, RIT, JATA. [Tuberculosis Annual Report 2011-(2) Childhood and elderly tuberculosis]. Kekkaku 2013; 88: 611-616.
33. Gava C, Malacarne J, Rios DP, et al. Tuberculosis in indigenous children in the Brazilian Amazon. Rev Saude Publica 2013; 47: 77-85.
34. Kapata N, Chanda-Kapata P, O'Grady J, et al. Trends in childhood tuberculosis in Zambia: a situation analysis. J Trop Pediatr 2013; 59: 134-139.
35. Gideon HP, Flynn JL. Latent tuberculosis: what the host "sees"? Immunol Res 2011; 50: 202-212.
36. Piccini P, Chiappini E, Tortoli E, et al. Clinical peculiarities of tuberculosis. BMC Infect Dis 2014; 14: Suppl. 1, S4.
37. Erkens CG, Kamphorst M, Abubakar I, et al. Tuberculosis contact investigation in low prevalence countries: a European consensus. Eur Respir J 2010; 36: 925-949.
38. Ford CB, Lin PL, Chase MR, et al. Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat Genet 2011; 43: 482-486.
39. Dheda K, Schwander SK, Zhu B, et al. The immunology of tuberculosis: from bench to bedside. Respirology 2010; 15: 433-450.
40. Walzl G, Ronacher K, Hanekom W, et al. Immunological biomarkers of tuberculosis. Nat Rev Immunol 2011; 11: 343-354.
41. Ottenhoff THM. The knowns and unknowns of the immunopathogenesis of tuberculosis. Int J Tuberc Lung Dis 2012; 16: 1424-1432.
42. Gourgouillon N, de Lauzanne A, Cottart CH, et al. TNF-a/IL-2 ratio discriminates latent from active tuberculosis in immunocompetent children: a pilot study. Pediatr Res 2012; 72: 370-374.
43. Kagina BM, Abel B, Scriba TJ, et al. Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns. Am J Respir Crit Care Med 2010; 182: 1073-1079.
44. de Beaucoudrey L, Samarina A, Bustamante J, et al. Revisiting human IL-12Rb1 deficiency: a survey of 141 patients from 30 countries. Medicine (Baltimore) 2010; 89: 381-402.
45. Boisson-Dupuis S, El Baghdadi J, Parvaneh N, et al. IL-12Rb1 deficiency in two of fifty children with severe tuberculosis from Iran, Morocco, and Turkey. PLoS One 2011; 6: e18524.
46. Mosaad YM, Soliman OE, Tawhid ZE, et al. Interferon-c +874 T/A and interleukin-10 -1082 A/G single nucleotide polymorphism in Egyptian children with tuberculosis. Scand J Immunol 2010; 72: 358-364.
47. Sun L, Jin YQ, Shen C, et al. Genetic contribution of CISH promoter polymorphisms to susceptibility to tuberculosis in Chinese children. PLoS One 2014; 9: e92020.
48. Alangari AA, Al-Zamil F, Al-Mazrou A, et al. Treatment of disseminated mycobacterial infection with high-dose IFN-c in a patient with IL-12Rb1 deficiency. Clin Dev Immunol 2011; 2011: 691956.
49. Maes M, Verhagen LM, Ortega D, et al. Influence of Bacille Calmette-Guérin on tuberculin skin testing in Venezuelan Amerindians in high tuberculosis burden areas. J Infect Dev Ctries 2014; 8: 176-183.
50. Cobat A, Hoal EG, Gallant CJ, et al. Identification of a major locus, TNF1, that controls BCG-triggered tumor necrosis factor production by leukocytes in an area hyperendemic for tuberculosis. Clin Infect Dis 2013; 57: 963-970.
51. Lapphra K, Sutthipong C, Foongladda S, et al. Drug-resistant tuberculosis in children in Thailand. Int J Tuberc Lung Dis 2013; 17: 1279-1284.
52. Graham SM, Ahmed T, Amanullah F, et al. Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel. J Infect Dis 2012; 205: Suppl. 2, S199-S208.
53. Mazurek GH, Jereb J, Vernon A, et al. Updated guidelines for using interferon c release assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep 2010; 59: 1-25.
54. Kampmann B, Whittaker E, Williams A, et al. Interferon-c release assays do not identify more children with active tuberculosis than the tuberculin skin test. Eur Respir J 2009; 33: 1374-1382.
55. Haustein T, Ridout DA, Hartley JC, et al. The likelihood of an indeterminate test result from a whole-blood interferon-c release assay for the diagnosis of Mycobacterium tuberculosis infection in children correlates with age and immune status. Pediatr Infect Dis J 2009; 28: 669-673.
56. Yassin MA, Petrucci R, Garie KT, et al. Use of tuberculin skin test, IFN-c release assays and IFN-c-induced protein- 10 to identify children with TB infection. Eur Respir J 2013; 41: 644-648.
57. Diel R, Loddenkemper R, Zellweger JP, et al. Old ideas to innovate tuberculosis control: preventive treatment to achieve elimination. Eur Respir J 2013; 42: 785-801.
58. Sester M, Sotgiu G, Lange C, et al. Interferon-c release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur Respir J 2011; 37: 100-111.
59. Chiappini E, Bonsignori F, Accetta G, et al. Interferon-c release assays for the diagnosis of Mycobacterium tuberculosis infection in children: a literature review. Int J Immunopathol Pharmacol 2012; 25: 335-343.
60. Mandalakas AM, van Wyk S, Kirchner L, et al. Detecting tuberculosis infection in HIV-infected children: a study of diagnostic accuracy, confounding and interaction. Pediatr Infect Dis J 2013; 32: e111-e118.
61. Lucas M, Nicol P, McKinnon E, et al. A prospective large-scale study of methods for the detection of latent Mycobacterium tuberculosis infection in refugee children. Thorax 2010; 65: 442-448.
62. Chegou NN, Detjen AK, Thiart L, et al. Utility of host markers detected in Quantiferon supernatants for the diagnosis of tuberculosis in children in a high-burden setting. PLoS One 2013; 8: e64226.
63. World Health Organization. Guidance for National Tuberculosis Programmes on the Management of Tuberculosis in Children. 2nd Edn. Geneva, WHO, 2014.
64. Tuyisenge L, Ndimubanzi CP, Ndayisaba G, et al. Evaluation of latent class analysis and decision thresholds to guide the diagnosis of pediatric tuberculosis in a Rwandan reference hospital. Pediatr Infect Dis J 2010; 29: e11-e18.
65. Thomas TA, Heysell SK, Moodley P, et al. Intensified specimen collection to improve tuberculosis diagnosis in children from Rural South Africa, an observational study. BMC Infect Dis 2014; 14: 11.
66. Moore HA, Apolles P, de Villiers PJ, et al. Sputum induction for microbiological diagnosis of childhood pulmonary tuberculosis in a community setting. Int J Tuberc Lung Dis 2011; 15: 1185-1190.
67. Zar HJ, Workman L, Isaacs W, et al. Rapid molecular diagnosis of pulmonary tuberculosis in children using nasopharyngeal specimens. Clin Infect Dis 2012; 55: 1088-1095.
68. Goussard P, Gie RP, Kling S, et al. The diagnostic value and safety of transbronchial needle aspiration biopsy in children with mediastinal lymphadenopathy. Pediatr Pulmonol 2010; 45: 1173-1179.
69. Achkar JM, Lawn SD, Moosa MY, et al. Adjunctive tests for diagnosis of tuberculosis: serology, ELISPOT for site- specific lymphocytes, urinary lipoarabinomannan, string test, and fine needle aspiration. J Infect Dis 2011; 204: Suppl. 4, S1130-S1141.
70. Bates M, O'Grady J, Maeurer M, et al. Assessment of the Xpert MTB/RIF assay for diagnosis of tuberculosis with gastric lavage aspirates in children in sub-Saharan Africa: a prospective descriptive study. Lancet Infect Dis 2013; 13: 36-42.
71. Anderson ST, Kaforou M, Brent AJ, et al. Diagnosis of childhood tuberculosis and host RNA expression in Africa. N Engl J Med 2014; 370: 1712-1723.
72. Ha DT, Lan NTN, Wolbers M, et al. Microscopic observation drug susceptibility assay (MODS) for early diagnosis of tuberculosis in children. PLoS One 2009; 4: e8341.
73. Nhu NT, Ha DT, Anh ND, et al. Evaluation of XpertMTB/RIF and MODS assay for the diagnosis of pediatric tuberculosis. BMC Infect Dis 2013; 13: 31.
74. Weyer K, Mirzayev F, Migliori GB, et al. Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF. Eur Respir J 2013; 42: 252-271.
75. Nicol MP, Workman L, Isaacs W, et al. Accuracy of the Xpert MTB/RIF test for the diagnosis of pulmonary tuberculosis in children admitted to hospital in Cape Town, South Africa: a descriptive study. Lancet Infect Dis 2011; 11: 819-824.
76. World Health Organization. Automated Real-Time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF System for the Diagnosis of Pulmonary and Extrapulmonary TB in Adults and Children: Policy Update (WHO/HTM/TB/2013.14). Geneva, WHO, 2013.
77. Tortoli E, Russo C, Piersimoni C, et al. Clinical validation of Xpert MTB/RIF for the diagnosis of extrapulmonary tuberculosis. Eur Respir J 2012; 40: 442-447.
78. Dodd LE, Wilkinson RJ. Diagnosis of pediatric tuberculosis: the culture conundrum. Lancet Infect Dis 2013; 13: 3-4.
79. Verhagen LM, Zomer A, Maes M, et al. A predictive signature gene set for discriminating active from latent tuberculosis in Warao Amerindian children. BMC Genomics 2013; 14: 74.
80. Nicol MP, Allen V, Workman L, et al. Urine lipoarabinomannan testing for diagnosis of pulmonary tuberculosis in children: a prospective study. Lancet Glob Health 2014; 2: e278-e284.
81. Kolk A, Hoelscher M, Maboko L, et al. Electronic-nose technology using sputum samples in diagnosis of patients with tuberculosis. J Clin Microbiol 2010; 48: 4235-4238.
82. Amanullah F, Ashfaq M, Khowaja S, et al. High tuberculosis prevalence in children exposed at home to drug- resistant tuberculosis. Int J Tuberc Lung Dis 2014; 18: 520-527.
83. Morcos W, Morcos M, Doss S, et al. Drug-resistant tuberculosis in Egyptian children using Etest. Minerva Pediatr 2008; 60: 1385-1392.
84. Esposito S, D'Ambrosio L, Tadolini M, et al. ERS/WHO Tuberculosis Consilium assistance with extensively drug- resistant tuberculosis management in a child: case study of compassionate delamanid use. Eur Respir J 2014; 44: 811-815.
85. Ettehad D, Schaaf HS, Seddon JA, et al. Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12: 449-456.
86. Seddon JA, Hesseling AC, Willemse M, et al. Culture-confirmed multidrug-resistant tuberculosis in children: clinical features, treatment, and outcome. Clin Infect Dis 2012; 54: 157-166.
87. Williams B, Ramroop S, Shah P, et al. Multidrug-resistant tuberculosis in UK children: presentation, management and outcome. Eur Respir J 2013; 41: 1456-1458.
88. Schaaf HS, Marais BJ, Hesseling AC, et al. Surveillance of antituberculosis drug resistance among children from the Western Cape Province of South Africa - an upward trend. Am J Public Health 2009; 99: 1486-1490.
89. World Health Organization. Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis: 2011 Update. Geneva, WHO, 2011
90. Delacourt C. Particularités de la tuberculose chez l'enfant [Specific features of tuberculosis in childhood]. Rev Mal Respir 2011; 28: 529-541.
91. Swingler GH, du Toit G, Andronikou S, et al. Diagnostic accuracy of chest radiography in detecting mediastinal lymphadenopathy in suspected pulmonary tuberculosis. Arch Dis Child 2005; 90: 1153-1156.
92. Hatherill M, Verver S, Mahomed H. Consensus statement on diagnostic end points for infant tuberculosis vaccine trials. Clin Infect Dis 2012; 54: 493-501.
93. Gwee A, Pantazidou A, Ritz N, et al. To x-ray or not to x-ray? Screening asymptomatic children for pulmonary TB: a retrospective audit. Arch Dis Child 2013; 98: 401-404.
94. Goussard P, Gie RP, Kling S, et al. The outcome of infants younger than 6 months requiring ventilation for pneumonia caused by Mycobacterium tuberculosis. Pediatr Pulmonol 2008; 43: 505-510.
95. Arlaud K, Gorincour G, Bouvenot J, et al. Could CT scan avoid unnecessary flexible bronchoscopy in children with active pulmonary tuberculosis? A retrospective study. Arch Dis Child 2010; 95: 125-129.
96. Gupta A, Pauliah S, Urquhart DS, et al. Endobronchial polyp secondary to pulmonary tuberculosis. Arch Dis Child 2009; 94: 230.
97. Goussard P, Gie RP, Kling S, et al. Bronchoscopic assessment of airway involvement in children presenting with clinically significant airway obstruction due to tuberculosis. Pediatr Pulmonol 2013; 48: 1000-1007.
98. Abuogi LL, Mwachari C, Leslie HH, et al. Impact of expanded antiretroviral use on incidence and prevalence of tuberculosis in children with HIV in Kenya. Int J Tuberc Lung Dis 2013; 17: 1291-1297.
99. Venturini E, Turkova A, Chiappini E, et al. Tuberculosis and HIV co-infection in children. BMC Infect Dis 2014; 14: Suppl. 1, S5.
100. Yotebieng M, Van Rie A, Moultrie H, et al. Effect on mortality and virological response of delaying antiretroviral therapy initiation in children receiving tuberculosis treatment. AIDS 2010; 24: 1341-1349.
101. Pefura Yone EW, Evouna Mbarga A, Kuaban C. Impact de l'infection a VIH sur la tuberculose de l'enfant a Yaounde, Cameroun [The impact of HIV infection on childhood tuberculosis in Yaounde, Cameroon]. Rev Mal Respir 2012; 29: 1095-1103.
102. Hailu D, Abegaz WE, Belay M. Childhood tuberculosis and its treatment outcomes in Addis Ababa: a 5-years retrospective study. BMC Pediatr 2014; 14: 61.
103. van Leth F, Kampmann B. Embracing the challenges of HIV-TB co-infection in children. Int J Tuberc Lung Dis 2014; 18: 379.
104. Thee S, Seddon JA, Donald PR, et al. Pharmacokinetics of isoniazid, rifampin, and pyrazinamide in children younger than two years of age with tuberculosis: evidence for implementation of revised World Health Organization recommendations. Antimicrob Agents Chemother 2011; 55: 5560-5567.
105. Schaaf HS, Victor TC, Engelke E, et al. Minimal inhibitory concentration of isoniazid in isoniazid-resistant Mycobacterium tuberculosis isolates from children. Eur J Clin Microbiol Infect Dis 2007; 26: 203-205.
106. Satyanarayana S, Shivashankar R, Vashist RP, et al. Characteristics and programme-defined treatment outcomes among childhood tuberculosis (TB) patients under the National TB Programme in Delhi. PLoS One 2010; 5: e13338.
107. Menon PR, Lodha R, Sivanandan S, et al. Intermittent or daily short course chemotherapy for tuberculosis in children: meta-analysis of randomized controlled trials. Indian Pediatr 2010; 47: 67-73.
108. Chang KC, Leung CC, Grosset J, et al. Treatment of tuberculosis and optimal dosing schedules. Thorax 2011; 66: 997-1007.
109. Ormerod LP. Drug therapy for children with tuberculosis. Arch Dis Child 2012; 97: 1097-1101.
110. Thampi N, Stephens D, Rea E, et al. Unexplained deterioration during antituberculous therapy in children and adolescents: clinical presentation and risk factors. Pediatr Infect Dis J 2012; 31: 129-133.
111. Goussard P, Gie R. Airway involvement in pulmonary tuberculosis. Paediatr Respir Rev 2007; 8: 118-123.
112. van Dijk JH, Sutcliffe CG, Hamangaba F, et al. Effectiveness of efavirenz-based regimens in young HIV-infected children treated for tuberculosis: a treatment option for resource-limited settings. PLoS One 2013; 8: e55111.
113. Fairlie L, Beylis NC, Reubenson G, et al. High prevalence of childhood multi-drug resistant tuberculosis in Johannesburg, South Africa: a cross sectional study. BMC Infect Dis 2011; 11: 28.
114. Rose PC, Hallbauer UM, Seddon JA, et al. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children. Int J Tuberc Lung Dis 2012; 16: 1588-1593.
115. Faurholt-Jepsen D, Range N, Praygod G, et al. BCG protects against tuberculosis irrespective of HIV status: a matched case-control study in Mwanza, Tanzania. Thorax 2013; 68: 288-289.
116. Zelner JL, Murray MB, Becerra MC, et al. Bacillus Calmette-Guérin and isoniazid preventive therapy protect contacts of patients with tuberculosis. Am J Respir Crit Care Med 2014; 189: 853-859.
117. Shann F. Nonspecific effects of vaccines and the reduction of mortality in children. Clin Ther 2013; 35: 109-114.
118. Trunz BB, Fine P, Dye C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 2006; 367: 1173-1180.
119. Dara M, Acosta CD, Rusovich V, et al. Bacille Calmette-Guérin vaccination: the current situation in Europe. Eur Respir J 2014; 43: 24-35.
120. Guthmann JP, Antoine D, Fonteneau L, et al. Assessing BCG vaccination coverage and incidence of paediatric tuberculosis following two major changes in BCG vaccination policy in France. Euro Surveill 2011; 16: 19774.
121. Guthmann JP, Chauvin P, Le Strat Y, et al. Family history of immigration from a tuberculosis endemic country and low family income are associated with a higher BCG vaccination coverage in Ile-de-France region, France. Vaccine 2013; 31: 5666-5671.
122. Montagnani C, Chiappini E, Galli L, et al. Vaccine against tuberculosis: what's new? BMC Infect Dis 2014; 14: Suppl. 1, S2.
123. Ayieko J, Abuogi L, Simchowitz B, et al. Efficacy of isoniazid prophylactic therapy in prevention of tuberculosis in children: a meta-analysis. BMC Infect Dis 2014; 14: 91.
124. Mandalakas AM, Hesseling AC, Gie RP, et al. Modelling the cost-effectiveness of strategies to prevent tuberculosis in child contacts in a high-burden setting. Thorax 2013; 68: 247-255.
125. Zar HJ, Cotton MF, Strauss S, et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomized controlled trial. BMJ 2007; 334: 136.
126. Gray DM, Workman LJ, Lombard CJ, et al. Isoniazid preventive therapy in HIV-infected children on antiretroviral therapy: a pilot study. Int J Tuberc Lung Dis 2014; 18: 322-327.
127. Gray DM, Zar H, Cotton M. Impact of tuberculosis preventive therapy on tuberculosis and mortality in HIV- infected children. Cochrane Database Syst Rev 2009; 1: CD006418.
128. Leung CC, Rieder HL, Lange C, et al. Treatment of latent infection with Mycobacterium tuberculosis: update 2010. Eur Respir J 2011; 37: 690-711.
129. Madhi SA, Nachman S, Violari A, et al. Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. N Engl J Med 2011; 365: 21-31.
130. Cattamanchi A, Dantes RB, Metcalfe JZ, et al. Clinical characteristics and treatment outcomes of patients with isoniazid-monoresistant tuberculosis. Clin Infect Dis 2009; 48: 179-185.
131. Spyridis NP, Spyridis PG, Gelesme A, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis 2007; 45: 715-722.
132. Gwee A, Coghlan B, Curtis N. Question 1: what are the options for treating latent TB infection in children? Arch Dis Child 2013; 98: 468-474.
133. Sharma SK, Sharma A, Kadhiravan T, et al. Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst Rev 2013; 7: CD007545.
134. D'Ambrosio L, Dara M, Tadolini M, et al. Tuberculosis elimination: theory and practice in Europe. Eur Respir J 2014; 43: 1410-1420.
135. Voniatis C, Migliori GB, Voniatis M, et al. Tuberculosis elimination: dream or reality? The case of Cyprus. Eur Respir J 2014; 44: 543-546.